Accelerating Cortical Thinning: Unique to Dementia or Universal in Aging?

Anders M. Fjell,Lars T. Westlye,Håkon Grydeland,Inge Amlien,Thomas Espeseth,Ivar Reinvang,Naftali Raz,Anders M Dale,Kristine B. Walhovd,,

DOI: https://doi.org/10.1093/cercor/bhs379

IF: 4.861

2012-12-12

Cerebral Cortex

Abstract:Does accelerated cortical atrophy in aging, especially in areas vulnerable to early Alzheimer's disease (AD), unequivocally signify neurodegenerative disease or can it be part of normal aging? We addressed this in 3 ways. First, age trajectories of cortical thickness were delineated cross-sectionally (n = 1100) and longitudinally (n = 207). Second, effects of undetected AD on the age trajectories were simulated by mixing the sample with a sample of patients with very mild to moderate AD. Third, atrophy in AD-vulnerable regions was examined in older adults with very low probability of incipient AD based on 2-year neuropsychological stability, CSF Aβ(1-42) levels, and apolipoprotein ε4 negativity. Steady decline was seen in most regions, but accelerated cortical thinning in entorhinal cortex was observed across groups. Very low-risk older adults had longitudinal entorhinal atrophy rates similar to other healthy older adults, and this atrophy was predictive of memory change. While steady decline in cortical thickness is the norm in aging, acceleration in AD-prone regions does not uniquely signify neurodegenerative illness but can be part of healthy aging. The relationship between the entorhinal changes and changes in memory performance suggests that non-AD mechanisms in AD-prone areas may still be causative for cognitive reductions.

neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: Is accelerated cortical atrophy in the elderly limited to patients with dementia, or is it also part of normal aging? Specifically, researchers want to explore whether, during the aging process, especially in Alzheimer's disease (AD) -susceptible regions, accelerated cortical atrophy clearly indicates neurodegenerative diseases, or it can also be part of normal aging. To answer this question, researchers adopted three methods:

1. **Cross - sectional and longitudinal analysis**: Depict the cortical thickness change trajectories of different age groups through cross - sectional (n = 1,100) and longitudinal (n = 207) samples.
2. **Simulating undetected AD effects**: Simulate the impact of undetected AD on age trajectories by mixing samples of mild - to - moderate AD patients into samples of healthy elderly people.
3. **Analysis of low - risk elderly groups**: Select elderly participants with a very low early - stage AD risk (based on two - year neuropsychological stability, cerebrospinal fluid Aβ1 - 42 levels, and APOE ε4 negativity), and examine the cortical atrophy in AD - susceptible regions in these low - risk elderly groups.

Through these methods, researchers aim to distinguish the differences between cortical atrophy in the normal aging process and that caused by neurodegenerative diseases, especially focusing on the changes in cortical thickness in Alzheimer's disease - susceptible regions (such as the entorhinal cortex). This helps to better understand the relationship between normal aging and age - related dementia, as well as how to more accurately identify and diagnose early - stage dementia.